Summit Therapeutics
Logotype for Summit Therapeutics Inc

Summit Therapeutics (SMMT) investor relations material

Summit Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Summit Therapeutics Inc
Q3 2026 earnings summary14 Nov, 2026

Executive summary

  • Ivonescimab programs span NSCLC, colorectal, urothelial, renal and biliary tract cancers, with additional solid-tumor collaborations.

  • AstraZeneca’s $2.0 billion investment closed Oct. 5, supporting accelerated development; Sept. 30 cash, cash equivalents and short-term investments totaled $629.8 million.

  • Akeso-reported Phase III studies showed OS benefits in PD-L1-positive NSCLC and biliary tract cancer.

Financial highlights

  • Q3 GAAP operating expenses were $214.6 million vs. $234.2 million YoY; R&D was $169.1 million vs. $131.1 million, while G&A was $45.5 million vs. $103.1 million.

  • Q3 GAAP net loss was $208.4 million, or $0.26 per share, vs. $231.8 million, or $0.31 per share; non-GAAP net loss was $160.7 million, or $0.20 per share.

  • Nine-month GAAP operating expenses were $630.3 million vs. $869.5 million; net loss was $613.5 million, or $0.78 per share, vs. $860.4 million, or $1.16 per share.

Outlook and guidance

  • HARMONI’s PDUFA action date was Nov. 14, 2026; a conference call was planned following FDA action.

  • HARMONI-3 squamous-cohort primary PFS analysis and early OS interim were expected in Q4 2026; non-squamous PFS events were expected in H1 2027.

  • HARMONI-GI3 enrollment was expected to complete in Q3 2027; HARMONI-7 enrollment was expected to complete in 2027.

  • Initial Arcus-collaboration data for casdatifan in clear-cell RCC were expected by mid-2027; further global Phase III expansion was planned.

  • R&D and G&A expenses were expected to rise as clinical development, infrastructure and headcount expand.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Summit Therapeutics earnings date

Logotype for Summit Therapeutics Inc
Investor update30 Nov, 2026
Summit Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Summit Therapeutics earnings date

Logotype for Summit Therapeutics Inc
Investor update30 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.